• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

I See a Direction for Compass Pathways

It may have a tough pill to swallow right now, but I'm still optimistic about psilocybin in general, and especially Cybin.
By TIMOTHY COLLINS
Nov 09, 2021 | 04:42 PM EST
Stocks quotes in this article: CMPS, CYBN

It's been a roller coaster ride for Compass Pathways ( CMPS)  shares over the past two days.
 
Unfortunately, the coaster ran out of track and crashed to the ground by lunchtime Tuesday. The end result is a stock that broke above $60 for a brief moment in the pre-market was trading at nearly half that price by the time lunch ended for many people on the East Coast.
 
This morning, the company released both its quarterly report and the topline results for its phase IIb COMP360 psilocybin therapy for treatment-resistant depression (TRD). In terms of the quarterly results, no one expects much. This is still a company in research, development, and testing mode, so it should be no surprise the market focused on the topline results from its current trial more than the financial numbers.
 
Initially, the market responded favorable, likely driven by the headline lead "Positive topline results..." and they were positive, but they were far from perfect. That's the honest truth. But did anyone expect the first sizable trial to produce pristine results?
 
The larger, single 25mg does showed significant results compared to the 1mg group with lasting remission. Unfortunately, the 10mg group didn't experience statistical improvement. That was likely one reason the market faded the initial pop. The concern may have been the 12 patients that expressed suicidal thoughts or behavior. Half came from the 10mg group and an additional five from the 25mg group. The question became did the drug cause that behavior or did it simply not work for them?
 
What the study does show is psilocybin has the potential to help; however, it is not yet a panacea or even a standalone treatment based on these results. It also pointed to the current need for a high dose and reinforces the need for treatment centers. In short, it won't be the first line treatment any time soon.
 
Shares did manage the $30 support level and regain the 21-day simple moving average (SMA) by the close. It's not a pretty picture but the $30 level becomes a clear stop for holders or new buyers.
 
 
I'm still optimistic in the space.
 
This type of volatility is unpleasant, but also expected. All right, maybe this week's action is extreme, but that's going to continue as long as we have trials and data. Additionally, I'm looking forward to Cybin's ( CYBN) use of Kernel Flow Technology as they may be able to further the understanding on what happened or did not happen in the brains of the 12 individuals who suffered from suicidal thoughts/behavior. As much as we need data, we also need an understanding on what may or may not have worked. Self-reporting surveys don't get us completely across that line. Kernel might, though, which is why I remain high on Cybin.
 
 
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Tim Collins was long CYBN.

 
TAGS: Investing | Options | Stocks | Biotechnology | Pharmaceuticals | Cannabis

More from Stocks

The Bull Is Out of the Gate

Helene Meisler
Jun 9, 2023 6:00 AM EDT

Look how quickly we got bulled up. Let's check sentiment, the surveys and the International Securities Exchange call/put ratio.

A Roundabout on Wall Street

James "Rev Shark" DePorre
Jun 8, 2023 4:25 PM EDT

The big caps turn out big again, with Apple, Microsoft and Nvidia at the wheel.

Ignore Carvana's Backseat Drivers

Ed Ponsi
Jun 8, 2023 1:09 PM EDT

I'll take a ride with CVNA, but I will wear my safety belt -- and know when to get out.

GameStop Needs to Unlock a Secret Door to a New Business

Stephen Guilfoyle
Jun 8, 2023 12:27 PM EDT

After another GME earnings blunder and change of players, I see the stock as this: pure speculation with a strong balance sheet. But I believe the company can find a way to the next level -- though it could get zapped before getting there.

Here's a Stock I'm Watching as the Rotation Gets Stuck in Reverse

James "Rev Shark" DePorre
Jun 8, 2023 11:46 AM EDT

I'm eyeing this biotech name as the Nasdaq 100 moves up -- again -- and small calls slip.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:19 PM EDT CHRIS VERSACE

    AAP Podcast: This Company Is Not Going 'Solo'

    Listen in as I talk with the very diversified Solo...
  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login